{
    "clinical_study": {
        "@rank": "80821", 
        "brief_summary": {
            "textblock": "To assess the tolerability and safety of OPC-14117. To evaluate effects of OPC-14117 on\n      cognitive function, quality of life, and activities of daily living."
        }, 
        "brief_title": "Parallel Group, Placebo-Controlled, Tolerability, Safety, and Efficacy Study of OPC-14117 in HIV Dementia", 
        "condition": [
            "Cognitive Disorders", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "AIDS Dementia Complex", 
                "Cognition Disorders", 
                "Dementia"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients receive OPC-14117 or placebo bid for 12 weeks, followed by 12 weeks of open label\n      therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  HIV seropositivity.\n\n          -  Cognitive impairment.\n\n        Prior Medication:\n\n        Allowed:\n\n          -  Prior OPC-14117 other than on the current study.\n\n          -  Antiretroviral therapy if stable for 6 weeks prior to study entry (12 weeks for\n             stavudine).\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Current opportunistic CNS infection (i.e., toxoplasmosis or cryptococcal meningitis).\n\n          -  Severe pre-morbid psychiatric illness including schizophrenia and major depression\n             that would interfere with protocol compliance.\n\n          -  CNS neoplasms.\n\n          -  Any other clinically significant condition or laboratory abnormality that would\n             interfere with ability to participate on study.\n\n          -  Current participation in other drug studies.\n\n        Patients with the following prior conditions are excluded:\n\n          -  Past history of opportunistic CNS infection (i.e., toxoplasmosis or cryptococcal\n             meningitis).\n\n          -  History of chronic neurological disorders such as serious head injury, documented\n             stroke, multiple sclerosis, uncontrolled epilepsy, Tourette's syndrome, and other\n             neurodegenerative processes such as Huntington's disease.\n\n          -  History of adverse reaction / allergy to OPC-14117.\n\n          -  Prior participation on this study.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Other investigational drugs within the past 30 days. Alcoholism within past 6 months\n             (more than 2 drinks daily)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "30", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002148", 
            "org_study_id": "242A", 
            "secondary_id": "02-D94"
        }, 
        "intervention": {
            "intervention_name": "OPC 14117", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Free Radical Scavengers"
        }, 
        "keyword": [
            "Cognition Disorders", 
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex", 
            "Free Radical Scavengers", 
            "Antioxidants", 
            "OPC 14117"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "212876965"
                    }, 
                    "name": "Johns Hopkins Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }, 
                    "name": "Columbia Univ"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14642"
                    }, 
                    "name": "Univ of Rochester Med Ctr"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Parallel Group, Placebo-Controlled, Tolerability, Safety, and Efficacy Study of OPC-14117 in HIV Dementia", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "reference": {
            "PMID": "9222182", 
            "citation": "Safety and tolerability of the antioxidant OPC-14117 in HIV-associated cognitive impairment. The Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders. Neurology. 1997 Jul;49(1):142-6."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002148"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Rochester", 
                "agency_class": "Other"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 1996"
    }, 
    "geocoordinates": {
        "Columbia Univ": "40.714 -74.006", 
        "Johns Hopkins Hosp": "39.29 -76.612", 
        "Univ of Rochester Med Ctr": "43.161 -77.611"
    }
}